Health Economics and Policy Analysis Centre (HEPAC), Institute for Lifecourse & Society (ILAS), CURAM, SFI Research Centre for Medical Devices, NUI Galway, University Road, Galway H91 TK33, Ireland.
Health Economics and Policy Analysis Centre (HEPAC), CURAM, SFI Research Centre for Medical Devices, NUI Galway, University Road, Galway H91 TK33, Ireland.
Fam Pract. 2022 Sep 24;39(5):826-833. doi: 10.1093/fampra/cmac006.
BACKGROUND: Multimorbidity is a major public health concern. Complex interventions, incorporating individualized care plans, may be appropriate for patients with multimorbidity given their individualized and variable needs. There is a dearth of evidence on the cost-effectiveness of complex multimorbidity interventions. OBJECTIVE: This study examines the cost-effectiveness of a 6-week occupational therapy-led self-management support programme (OPTIMAL) for adults with multimorbidity. METHODS: Economic evaluation, from a healthcare perspective, was conducted alongside a randomized controlled trial of 149 adults with multimorbidity. Intervention was the OPTIMAL programme with a comparison of usual primary care. Incremental costs, quality-adjusted life years (QALYs) gained, and expected cost-effectiveness were estimated at 6 months and uncertainty was explored using cost-effectiveness acceptability curves. RESULTS: The intervention was associated with a mean improvement in QALYs gained of 0.031 per patient (P-value: 0.063; 95% confidence intervals [CIs]: -0.002 to 0.063) and a mean reduction in total costs of €2,548 (P-value: 0.114; 95% CIs: -5,606 to 509) per patient. At cost-effectiveness threshold values of €20,000 and €45,000 per QALY, the probability of the intervention being cost-effective was estimated to be 0.951 and 0.958, respectively. The results remained consistent across all subgroups examined. CONCLUSIONS: This study adds to the limited evidence base on the cost-effectiveness of complex interventions for multimorbidity, and highlights the potential for the OPTIMAL programme to be cost-effective. Further studies are warranted to explore the clinical and cost-effectiveness of complex interventions for the multimorbidity patient population, and for subgroups within it. TRIAL REGISTRATION: Trial number: ISRCTN67235963.
背景:多种疾病并存是一个主要的公共卫生问题。鉴于患者的个体化和多变的需求,包含个体化护理计划的复杂干预措施可能适用于多种疾病并存的患者。目前,关于复杂多种疾病干预措施的成本效益证据很少。
目的:本研究旨在评估 6 周职业治疗主导的自我管理支持计划(OPTIMAL)治疗多种疾病并存的成年人的成本效益。
方法:从医疗保健的角度进行经济评估,同时对 149 名多种疾病并存的成年人进行了一项随机对照试验。干预措施是 OPTIMAL 计划,与常规初级保健进行比较。在 6 个月时估计增量成本、获得的质量调整生命年(QALYs)和预期成本效益,并使用成本效益接受性曲线探索不确定性。
结果:干预组患者获得的 QALY 平均提高 0.031 个(P 值:0.063;95%置信区间 [CI]:-0.002 至 0.063),总费用平均降低 2548 欧元(P 值:0.114;95% CI:-5606 至 509)。在成本效益阈值为 20000 欧元和 45000 欧元/QALY 时,干预措施具有成本效益的概率估计分别为 0.951 和 0.958。在所有检查的亚组中,结果均保持一致。
结论:本研究增加了复杂干预措施治疗多种疾病并存的成本效益的有限证据基础,并强调了 OPTIMAL 计划具有成本效益的潜力。需要进一步研究来探索复杂干预措施对多种疾病并存患者人群及其亚组的临床和成本效益。
试验注册:试验编号:ISRCTN67235963。
Int J Technol Assess Health Care. 2017-10-11
Int J Environ Res Public Health. 2025-5-13
Hong Kong J Occup Ther. 2025-4-3
Ageing Res Rev. 2017-5-13
Arch Gerontol Geriatr. 2016
Cochrane Database Syst Rev. 2016-3-14
Health Qual Life Outcomes. 2015-10-15